Anavex life sciences appoints senior vp of regulatory affairs

New york, nov. 06, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including alzheimer's disease, parkinson's disease, rett syndrome, and other central nervous system (cns) diseases, today announced the appointment of david goldberger, rph, mls as senior vice president regulatory affairs. mr. goldberger brings over 40 years of pharmacy practice and pharmaceutical industry experience and has most recently been with otsuka pharmaceuticals research and development (otsuka) as vice president global regulatory affairs, u.s. and europe. mr. goldberger will succeed retiring senior vice president regulatory affairs, emmanuel o fadiran, rph, ms, phd.
AVXL Ratings Summary
AVXL Quant Ranking